Skip to main content
. 2008 Mar;172(3):681–690. doi: 10.2353/ajpath.2008.070613

Table 2.

Transcriptional Regulation of Genes

Uridine Redoxal Redoxal + uridine Stavudine Stavudine + uridine Stavudine + redoxal Stavudine + redoxal + uridine
Cell cycle
 PCNA 1.2 ± 0.1 1.0 ± 0.1 0.8 ± 0.2 1.0 ± 0.1 0.8 ± 0.3 1.2 ± 0.1 1.1 ± 0.1
 UbcH10 1.2 ± 0.1* 1.1 ± 0.1 1.0 ± 0.2 1.2 ± 0.1* 0.8 ± 0.3 1.6 ± 0.1* 1.4 ± 0.2*
 p21 1.4 ± 0.1 2.7 ± 0.2** 2.2 ± 0.4* 2.1 ± 0.7* 1.9 ± 0.1* 4.2 ± 1.4* 2.7 ± 0.2***
 CDKN2A 1.2 ± 0.2 2.1 ± 0.6* 1.3 ± 0.7 3.6 ± 0.9** 1.9 ± 0.4*††† 8.1 ± 3.3** 2.2 ± 0.7*
Apoptosis
 BAD 1.4 ± 0.1 2.7 ± 0.6* 1.7 ± 0.4* 2.1 ± 1.0* 1.8 ± 0.1* 4.3 ± 1.8* 2.7 ± 0.1***
 BCL2 1.5 ± 0.1 3.2 ± 0.1*** 1.7 ± 0.3*††† 2.0 ± 0.5* 1.9 ± 0.2* 4.3 ± 1.3* 2.6 ± 0.2***
 BCL2L1 1.1 ± 0.1 2.7 ± 0.1*** 0.9 ± 0.2 1.4 ± 0.1* 1.1 ± 0.1 3.6 ± 0.1*** 1.4 ± 0.3†††
 BAX 1.1 ± 0.1 1.4 ± 0.1* 0.9 ± 0.2 1.1 ± 0.1 1.0 ± 0.1 1.9 ± 0.2* 1.1 ± 0.1††
 FAS 1.6 ± 0.4 4.9 ± 1.4* 1.0 ± 0.1††† 1.2 ± 0.2 1.4 ± 0.3 6.6 ± 0.3*** 1.6 ± 0.1**†††
 FASLG 1.5 ± 0.2 3.5 ± 0.4** 2.5 ± 0.7* 2.5 ± 1.2 1.8 ± 0.1* 7.0 ± 2.1** 3.8 ± 0.9**
 CASP3 1.1 ± 0.1 2.0 ± 0.1** 1.0 ± 0.2†† 1.2 ± 0.1 1.1 ± 0.1 3.0 ± 0.1*** 1.4 ± 0.1**†††
 CASP8 1.2 ± 0.1 1.9 ± 0.1* 1.0 ± 0.1†† 1.4 ± 0.1* 1.1 ± 0.1 2.5 ± 0.2** 1.3 ± 0.2††
 CASP9 1.3 ± 0.1* 2.2 ± 0.1*** 0.8 ± 0.1††† 1.3 ± 0.1* 1.3 ± 0.1* 3.6 ± 0.4** 1.7 ± 0.2**††
Mitochondrial energy metabolism
 COX IV 1.2 ± 0.1 2.1 ± 0.1** 1.0 ± 0.2 1.2 ± 0.1 1.2 ± 0.1* 2.8 ± 0.2** 1.5 ± 0.2††
 ATP9 1.3 ± 0.1 3.1 ± 0.3** 0.8 ± 0.4 1.4 ± 0.1* 1.0 ± 0.2 4.3 ± 0.1*** 1.7 ± 0.2**†††
 16S rRNA 1.2 ± 0.4 2.5 ± 1.1* 0.6 ± 0.1 4.1 ± 1.3** 1.3 ± 0.7††† 2.6 ± 0.6** 1.2 ± 0.8*
 ND1 0.8 ± 0.2 1.3 ± 0.2* 0.9 ± 0.1 1.1 ± 0.3 0.6 ± 0.1* 2.0 ± 0.6* 1.0 ± 0.4*
 COX I 0.9 ± 0.1 1.3 ± 0.4 0.6 ± 0.3 0.8 ± 0.3 1.1 ± 0.2 2.3 ± 0.4* 1.0 ± 0.2††
 ATP6 0.9 ± 0.1 1.6 ± 0.4 1.1 ± 0.2 0.8 ± 0.1 1.2 ± 0.6 2.9 ± 0.6** 0.7 ± 0.1*
 ND6 1.0 ± 0.1 2.7 ± 1.1* 1.5 ± 0.2* 1.1 ± 0.1 1.6 ± 0.5 5.3 ± 2.4* 1.2 ± 0.8*
Mitochondrial biogenesis
 POLG 1.0 ± 0.1 1.7 ± 0.5 0.9 ± 0.1 1.1 ± 0.2 1.4 ± 0.5 2.3 ± 0.8* 1.7 ± 0.8*
 PGC-1 1.6 ± 0.1 3.0 ± 0.4** 2.2 ± 0.3* 2.4 ± 0.1* 2.4 ± 0.1* 5.3 ± 2.3* 3.8 ± 0.3***
 TFAM 1.7 ± 0.6 1.9 ± 0.6 1.2 ± 0.4 1.2 ± 0.2 1.2 ± 0.2 1.8 ± 0.6 1.4 ± 0.3
Nucleotide metabolism
 DHFR 0.9 ± 0.1 1.9 ± 0.4* 0.5 ± 0.2* 0.9 ± 0.1 0.9 ± 0.1 2.6 ± 0.6* 1.0 ± 0.3*
 DGUOK 1.1 ± 0.1* 1.9 ± 0.1** 0.9 ± 0.1†† 1.1 ± 0.1 1.0 ± 0.1 2.6 ± 0.3** 1.2 ± 0.2††
 HPRT1 1.1 ± 0.1 1.1 ± 0.1 0.9 ± 0.2 1.2 ± 0.1* 1.1 ± 0.1 1.6 ± 0.1** 1.3 ± 0.2*
 DHODH 1.0 ± 0.2 0.8 ± 0.1 0.9 ± 0.2 1.1 ± 0.1 1.0 ± 0.1 1.3 ± 0.1** 1.2 ± 0.1
 UMPS 1.2 ± 0.1* 1.6 ± 0.1* 1.0 ± 0.2†† 1.1 ± 0.1 0.8 ± 0.2 2.4 ± 0.1* 1.3 ± 0.1*†††
 RRM1 1.0 ± 0.1* 1.6 ± 0.3* 0.8 ± 0.2 1.1 ± 0.1 1.0 ± 0.1 2.2 ± 0.2* 1.1 ± 0.1*†††
 TP 1.5 ± 0.1* 2.5 ± 0.1*** 1.7 ± 0.4* 4.8 ± 2.2* 1.8 ± 0.1*††† 11.0 ± 3.4* 2.5 ± 0.1***
 UPP1 1.1 ± 0.1* 1.4 ± 0.4 0.7 ± 0.3 1.4 ± 0.1* 0.8 ± 0.2 2.4 ± 0.9* 1.4 ± 0.2
 UCK2 1.2 ± 0.1 1.3 ± 0.1* 1.0 ± 0.2 1.2 ± 0.1 1.1 ± 0.1 1.9 ± 0.1** 1.4 ± 0.2
 TK1 0.9 ± 0.3* 1.6 ± 0.1* 0.9 ± 0.2 1.2 ± 0.1 1.1 ± 0.1 2.3 ± 0.1** 1.5 ± 0.2*
 DCK 1.0 ± 0.1 1.6 ± 0.1* 0.6 ± 0.2 0.9 ± 0.2 1.0 ± 0.1 2.6 ± 0.7* 1.2 ± 0.3
Oxidative stress
 GPX1 2.7 ± 2.4 5.2 ± 3.5 3.6 ± 1.7 4.6 ± 2.7 4.4 ± 3.1 8.3 ± 6.1 5.0 ± 3.8
 SOD1 1.1 ± 0.1 2.1 ± 0.1** 0.9 ± 0.1††† 1.4 ± 0.1* 0.8 ± 0.3 2.1 ± 0.5* 1.1 ± 0.4*
 SOD2 0.9 ± 0.4 2.1 ± 0.3* 1.4 ± 0.2 1.1 ± 0.2 1.8 ± 0.2* 2.6 ± 0.1*** 1.9 ± 1.1*
DNA repair
 UNG1 1.1 ± 0.1* 0.9 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 1.1 ± 0.1 2.0 ± 0.2* 1.3 ± 0.2*
 OGG1 1.2 ± 0.1* 1.6 ± 0.2* 1.0 ± 0.2 1.3 ± 0.1* 1.3 ± 0.1* 3.1 ± 0.3** 1.8 ± 0.2**
 APE1 1.1 ± 0.1 1.8 ± 0.1* 0.9 ± 0.2†† 1.2 ± 0.1* 1.1 ± 0.1 2.4 ± 0.2** 1.3 ± 0.2††

Values represent the fold difference (±SD) of mRNA copies after 10 days of HepG2 treatment with agents by comparison with unexposed cells. Three independent cell cultures were measured per agent added. Significance levels: 

*

P < 0.05, 

**

P < 0.01, 

***

P < 0.001 in comparison to controls (no uridine and no stavudine), 

P < 0.05, 

††

P < 0.01, 

†††

P < 0.001 in comparison to treatment without uridine. Bold entries represent significant up-regulation by a minimum factor of 2. 

Gene abbreviations: LMNB1, lamin B1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ACTB, actin beta; 36B4, ribosomal phosphoprotein P0; PCNA, proliferating cell nuclear antigen; UbcH10, ubiquitin-conjugating enzyme H10; p21, cyclin-dependent kinase inhibitor 1A; CDKN2A, cyclin-dependent kinase inhibitor 2A; BAD, BCL2 antagonist of cell death; BCL2, B-cell lymphoma protein 2; BCL2L1, BCL antagonist of cell death; BAX, BCL2-associated X protein; FAS, fast apoptotic stimulus; FASLG, Fas ligand; CASP3, caspase 3; CASP8, caspase 8; CASP9, caspase 9; COX IV, cytochrome c oxidase subunit IV; ATP9, ATP synthase subunit 9; 16S rRNA; ND1, NADH dehydrogenase subunit 1, complex I; COX I, cytochrome c-oxidase subunit 1; ATP6, ATP synthase subunit 6; ND6, NADH dehydrogenase subunit 6; POLG, polymerase-γ (catalytic subunit); PGC-1, peroxisome proliferator-activated γ co-activator-1; TFAM, mitochondrial transcription factor A; DHFR, dihydrofolate reductase; DGUOK, deoxyguanosine kinase; HPRT1, hypoxanthine phosphoribosyltransferase 1; DHODH, dihydroorotate dehydrogenase; UMPS, uridine monophosphate synthetase; RRM1, ribonucleotide reductase M1; TP, thymidine phosphorylase; UPP1, uridine phosphorylase 1; UCK2, uridine-cytidine kinase 2; TK1, thymidine kinase 1; DCK, deoxycytidine kinase; GPX1, glutathione peroxidase 1; SOD1, superoxide dismutase 1; SOD2, superoxide dismutase 2; UNG1, uracil-DNA glycosylase; OGG1, 8-oxoguanine DNA glycosylase; APE1, apurinic/apyrimidinic endonuclease 1.